•
Sep 30, 2022

Ultralife Q3 2022 Earnings Report

Reported an operating loss of $0.6 million and adjusted EBITDA of $1.3 million on revenue of $33.2 million.

Key Takeaways

Ultralife Corporation reported a revenue of $33.2 million for the third quarter ended September 30, 2022, representing a 52.7% increase compared to the same period last year. The company experienced an operating loss of $0.6 million and an adjusted EBITDA of $1.3 million.

Government/defense revenue doubled year-over-year.

Total company revenue increased by 53% due to government/defense revenue and the addition of Excell.

Backlog now exceeds $100 million, positioning the company well for near-term revenue increases.

Gross margins and profitability were pressured by production inefficiencies associated with supply chain disruptions and input cost inflation.

Total Revenue
$33.2M
Previous year: $21.8M
+52.7%
EPS
-$0.01
Previous year: -$0.05
-80.0%
Adjusted EBITDA
$1.3M
Gross Profit
$6.7M
Previous year: $5.1M
+31.4%

Ultralife

Ultralife

Ultralife Revenue by Segment

Forward Guidance

Ultralife is positioned well for near-term revenue increases and remains committed to advancing several transformational projects and new product opportunities to drive long-term revenue growth.